All In Biotech

Drug Trial Radar · NCT06752811

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

A Multi-center, Randomized, Open, Parallel-group, Positive Drug-controlled Phase III Clinical Trial for Evaluating the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Plus Gemcitabine and Paclitaxel for Injection (Albumin-bound) Plus Gemcitabine for Injection in the First-line Treatment of Metastatic Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

416

Planned (sponsor's estimate)

Start

Feb 5, 2025

Primary completion

Jul 1, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.

Conditions

  • Pancreatic Cancer Metastatic

Interventions

  • paclitaxel polymeric micelles for injectionDrug

    Paclitaxel polymeric micelles for injection at a dose of 300 mg/m2 (based on body surface area), administered on Day 1, with intravenous infusion for ≥ 3 hours, every 3 weeks as a cycle.

  • Gemcitabine Hydrochloride for InjectionDrug

    The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1 and D8 every 3 weeks.

  • Paclitaxel for Injection (albumin bound )Drug

    Patients in the control group will receive intravenous infusion of paclitaxel for Injection (albumin bound ) at a dose of 125 mg/m2 (based on body surface area), administered at D1, D8, and D15, every 4 weeks as a cycle.

  • Gemcitabine Hydrochloride for InjectionDrug

    The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1, D8, and D15 every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free-SurvivalTime frame: Randomization to measured PD or date of death from any cause(up to 36 months)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.